Enanta Pharmaceuticals, Inc. (ENTA) Research

Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.

Market snapshot

Symbol
ENTA
Price
$12.66
Day change
+0.16%
Market cap
$293.9M
P/E ratio
-4.37x
52-week range
6.435-17.15
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$48.20

Peer companies

  • Assembly Biosciences, Inc. (ASMB)
  • Atea Pharmaceuticals, Inc. (AVIR)
  • Caribou Biosciences, Inc. (CRBU)
  • Foghorn Therapeutics Inc. (FHTX)
  • Immuneering Corporation (IMRX)
  • Nautilus Biotechnology, Inc. (NAUT)
  • Prelude Therapeutics Incorporated (PRLD)
  • Pyxis Oncology, Inc. (PYXS)

Recent insider activity

  • Vance Terry — A-Award (20000 shares) on 2026-03-11
  • Russell Lesley — A-Award (20000 shares) on 2026-03-11
  • Peterson Kristine — A-Award (20000 shares) on 2026-03-11
  • Hata Yujiro S — A-Award (20000 shares) on 2026-03-11
  • FOLETTA MARK G — A-Award (20000 shares) on 2026-03-11

Open Enanta Pharmaceuticals, Inc. (ENTA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.